Early cancer detection saves lives. When cancer is found early, nearly nine out of 10 patients live five years or longer. But not all cancers are targeted by current screening tests. The routine cancer screenings that are available today can detect only five cancer types—lung, breast, cervical, colorectal, and prostate. But other cancers—such as liver, ovarian, and pancreatic—have no recommended routine screening options, and they are responsible for almost three-quarters of all cancer deaths.
If you add early testing capabilities to the ability to test for multiple cancers at the same time with a simple blood draw, you may be able to revolutionize cancer screening. Today, that possibility is becoming an increasingly likely scenario with multi-cancer early detection (MCED) tests. MCED tests rely on circulating tumor cell-free DNA to identify signs of early cancer in the blood without biopsy. With a single blood draw, these tests can both detect and localize multiple cancers throughout the body—before symptoms occur.
ACCC has launched an education project that is exploring the current state of MCED tests to develop best practices that cancer programs can adopt to fully integrate these tests as they become available. Specifically, this project will:
For more information on this project, please contact the ACCC Provider Education department.
Although multi-cancer early detection tests have the potential to revolutionize cancer screening, they are an emerging screening tool and testing has been limited in practice. In 2022, ACCC launched a comprehensive survey and a series of four focus groups to explore current perceptions, attitudes, and beliefs about multi-cancer early detection tests and how they can be best integrated into community programs and practices. Explore the results of this survey and learn about key considerations for implementation of this innovative screening tool.
Multi-cancer early detection tests are not yet widely available but could be in the next few years. In combination with existing standard of care recommendations, these tests hold the potential to revolutionize cancer screening, in part by detecting cancers for which no routine screening exists.
Association of Community Cancer Centers (ACCC) conducted a survey among its members between June 2022 and August 2022 to explore current attitudes, beliefs, and concerns related to this testing and the capacity multi-cancer early detection testing into cancer programs or practices.
Advancements in blood-based multi-cancer early detection screening platforms are on the horizon, bringing the latest advances in cancer screening technologies to patients and healthcare providers.
Thought leader, Dr. Chetan Bettegowda, shares insights with the multidisciplinary team and addresses questions related to their experiences with MCED in real time.
ACCC Applauds Senate Leaders for Introducing Bipartisan Legislation to Expand Medicare Coverage of Early Cancer Screenings
June 30, 2023
Rep. Sewell’s Legislation to Ensure Access to Groundbreaking Cancer Detection Tools Gains Substantial Momentum in Congress
Congresswoman Terri Sewell Press Release, June 23, 2021